learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
2 / 2 resultslearn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Research
5 / 416 resultsresearch Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy
A new AI-driven method shows promise for treating hair loss with a peptide-based drug.
research Traditional Scraping Combined with Copper-Curcumin Nanoparticle Oleogel for Therapy of Androgenic Alopecia
Using a special gel with copper and curcumin along with a scraping massage technique improved hair growth better than the common hair loss treatment, minoxidil.
research Acne Syndromes and Mosaicism
Understanding how acne develops in different diseases could lead to new treatments.
research Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders
New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
Community Join
5 / 56 resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community How is the GT20029 different to pyrilutamide as an androgenic antagonist
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.
The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.
community Anyone excited for CosmeRNA coming this month?
CosmeRNA, a new hair loss treatment, is expected to release soon and may become part of the "big three" treatments alongside finasteride and minoxidil. It works differently from finasteride by targeting androgen receptors in hair follicles, potentially offering fewer side effects.